When was budesonide oral suspension (Eohilia) last available on the market?

Budesonide oral suspension (Eohilia) is a new drug developed by Takeda specifically designed to treat eosinophilic esophagitis (EoE). The latest launch time of the drug is February 2024, and it is expected to be officially launched in the US market. In February 2024, budesonide oral suspension received approval from the U.S. Food and Drug Administration (FDA), becoming the first and only FDA-approved oral therapy for patients 11 years of age and older with eosinophilic esophagitis.

The launch of Eohilia marks a new stage in the field of drug treatment for eosinophilic esophagitis, especially for patients who cannot obtain effective relief through conventional treatments. The launch of Eohilia will provide patients with a new treatment option, which acts locally on the esophagus to reduce inflammation and eosinophil infiltration and improve symptoms such as dysphagia.

This drug will be packaged in a dosage form of 2mg/10mL in a convenient single-dose stick packaging to ensure that patients can use it conveniently and accurately in their daily lives. In addition, Eohilia's treatment plan is particularly suitable for patients aged 11 years and above with eosinophilic esophagitis, which can effectively relieve symptoms and reduce the occurrence of complications.

Although budesonide oral suspension has been approved and is about to be launched in the U.S. market, it has not yet been approved for marketing in other countries and regions, especially in China. Currently, the drug has not been introduced into the Chinese market, but it is expected that over time, similar treatment products may gradually enter these markets, bringing new hope to patients with eosinophilic esophagitis worldwide.

Overall, the launch of budesonide oral suspension provides a new option for the treatment of eosinophilic esophagitis and sets a new treatment standard worldwide. With the gradual improvement of market acceptance, this drug may become one of the first-choice drugs for the treatment of eosinophilic esophagitis globally in the future.

Reference materials:https://www.drugs.com/newdrugs/fda-approves-eohilia-budesonide-oral-suspension-eosinophilic-esophagitis-6190.html